Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xianzhao Yang
Observed names:
Xian-Zhao YANG,
Xian-zhao Yang
Institutions:
Beijing University of Chinese Medicine,
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Observed institutions:
Beijing University of Chinese Medicine,
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
ORCID:
0000-0002-6695-4929
Observed ORCID:
0000-0002-6695-4929
OpenAlex ID:
A5110865611
Systematic Review on Chinese Herbal Medicine Induced Liver Injury
2016
·
Peng Zhang
, Yongan Ye
, et al.
·
Evidence-based Complementary and Alternative Medicine
·
47
PDF
Comprehensive analysis of the chemical constituents in sulfur-fumigated Lonicerae Japonicae Flos using UHPLC-LTQ-Orbitrap mass spectrometry
2020
·
Zi-Han LIU
, Yu-Qi WANG
, et al.
·
Chinese Journal of Natural Medicines
·
23
Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial
2020
·
Xiaoke Li
, Daqiao Zhou
, et al.
·
Hepatology International
·
19
The efficacy and safety of addition of pegylated interferon to long-term nucleos(t)ide analogue therapy on functional cure of chronic hepatitis B patient: a systematic review and meta-analysis
2024
·
Xu Zhang
, Xianzhao Yang
, et al.
·
Frontiers in Pharmacology
·
17
PDF
Association between air pollution and risk of non-alcoholic fatty liver disease: an updated meta-analysis
2025
·
Xu Zhang
, Xianzhao Yang
, et al.
·
Frontiers in Public Health
·
9
PDF
Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial
2020
·
Xiao-ke Li
, Ming-xiang Zhang
, et al.
·
Chinese Journal of Integrative Medicine
·
8
Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial
2018
·
Yong-an Ye
, Xiao-ke Li
, et al.
·
Chinese Journal of Integrative Medicine
·
8
Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma
2022
·
Xu Cao
, Hening Chen
, et al.
·
Frontiers in Pharmacology
·
7
Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multi-center, double-blind, randomized controlled trial in China
2020
·
Xiaoke Li
, Ludan Zhang
, et al.
·
Trials
·
5
PDF
Efficacy and safety of umbilical therapy with the traditional Chinese medicine formulation Lishui Xiaogu cataplasm for cirrhotic ascites: protocol for a randomized controlled trial
2019
·
Xianzhao Yang
, Shuying Ru
, et al.
·
Trials
·
4
PDF
Identification of pseudo-immune tolerance for chronic hepatitis B patients: Development and validation of a non-invasive prediction model
2023
·
Shuo Li
, Zhiguo Li
, et al.
·
Frontiers in Public Health
·
2
PDF
A hybrid method for the determination of tubeimoside I in rat plasma after oral administration by LC‐IT‐TOF and UPLC‐MS/MS
2018
·
Ying Li
, Lifang Wang
, et al.
·
Biomedical Chromatography
·
2
Exploring the Molecular Mechanism of Niuxi-Mugua Formula in Treating Coronavirus Disease 2019 via Network Pharmacology, Computational Biology, and Surface Plasmon Resonance Verification
2023
·
Wei Wang
, Xu Cao
, et al.
·
Current Computer - Aided Drug Design
High Expression of SRD5A3 in Human Hepatocellular Carcinoma (HCC) Predicts Poor Prognosis: A Study Based on TCGA Data
2021
·
Jing Xue
, Xianzhao Yang
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
14
Citation count:
151
H-index:
7
I10-index:
4
Year
Topic
Type